Search results

From Self-sufficiency
Jump to: navigation, search
  • ...y]], [[multiple sclerosis]]<ref>Thrower BW. Relapse management in multiple sclerosis. Neurologist. 2009 Jan;15(1):1-5. Review. PMID 19131851</ref>, [[cluster he
    7 KB (872 words) - 16:41, 27 September 2010
  • *[[Multiple sclerosis]]<ref>{{cite news |title=Antibiotics 'could help slow MS' |url=http://news.
    20 KB (2,578 words) - 16:43, 27 September 2010
  • ...ates that clofazimine will be potentially used for treatment of [[multiple sclerosis]], [[rheumatoid arthritis]] and [[type 1 diabetes]]. Because the Kv1.3-high
    12 KB (1,651 words) - 16:43, 27 September 2010
  • ...ase]] (such as [[Crohn's disease]] and [[Ulcerative Colitis]]), [[multiple sclerosis]], [[autoimmune hepatitis]], [[atopic dermatitis]], [[Myasthenia Gravis]] a
    11 KB (1,410 words) - 16:49, 27 September 2010
  • ..., one time use products) or the [[crystallization]] of [[sodium acetate]] (multiple use products). ...illation]], [[Cardiac arrhythmia|arrhythmias]], and [[Sclerosis (medicine)|sclerosis]].<ref>[http://emedicine.medscape.com/article/766479-overview Hyperkalemia]
    14 KB (1,921 words) - 16:49, 27 September 2010
  • ...practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. | journal = Curr Med Res Opin | volume = 2 ...d by cerebral or [[spinal cord]] conditions such as [[stroke]], [[multiple sclerosis]], spinal cord injury (long-term treatment is coupled with other rehabilita
    78 KB (10,295 words) - 16:51, 27 September 2010
  • ...he causes of Parinaud syndrome include brain tumors (pinealomas), multiple sclerosis and brainstem infarction.
    7 KB (958 words) - 09:40, 20 September 2010
  • *[[Multiple sclerosis]] *[[Multiple sclerosis]]
    13 KB (1,694 words) - 09:40, 20 September 2010
  • [[Multiple Sclerosis]]-Optic Neuritis
    9 KB (1,273 words) - 09:40, 20 September 2010
  • ...nal |author=Judge S, Bever C |title=Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment |journal=Pharmac
    3 KB (420 words) - 09:44, 20 September 2010
  • ...m198463.htm FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis]</ref> Dalfampridine is marketed as '''Ampyra''' (pronounced "am-PEER-ah," ...nal |author=Judge S, Bever C |title=Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment |journal=Pharmac
    9 KB (1,146 words) - 09:44, 20 September 2010
  • ...l |author=Judge SI, Bever CT |title=Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment |journal=Pharmac
    5 KB (725 words) - 09:45, 20 September 2010
  • ...|| [[Joseph Honoré Simon Beau]] ||dermatology, internal medicine ||multiple, including trauma || ||transverse ridges on nails ...[[Bence Jones protein]] || [[Henry Bence Jones]] || hematology || [[multiple myeloma]] || ||
    59 KB (6,670 words) - 21:04, 21 September 2010
  • | [[Amyotrophic Lateral Sclerosis]] | [[Multiple chemical sensitivity|Multiple Chemical Sensitivities]]
    19 KB (2,282 words) - 21:04, 21 September 2010
  • ...used to indicate other names by which a condition is known. If there are multiple alternative names for a condition, they are separated by commas within the ...(Muehrcke's lines) [[Image:Nailbitebad.jpg|thumb|[[Onychotillomania]]|alt=Multiple, dystrophic, irregular, shortened fingernails]]
    177 KB (19,269 words) - 21:05, 21 September 2010
  • ...r a patient (examples include [[Christmas disease]], [[Amyotrophic lateral sclerosis|Lou Gehrig's disease]], [[Hartnup disease]] and [[Mortimer's disease]]). * Baló's disease or [[Balo concentric sclerosis]] &ndash; [[József Baló]]
    29 KB (3,290 words) - 21:05, 21 September 2010
  • * [[Mental retardation multiple nevi]] * [[Mesangial sclerosis, diffuse]]
    26 KB (2,392 words) - 21:07, 21 September 2010
  • * [[Sacral hemangiomas multiple congenital abnormalities]] * [[Spasticity multiple exostoses]]
    20 KB (1,973 words) - 21:07, 21 September 2010
  • * [[Pelizaeus-Merzbacher brain sclerosis]] * [[Primary lateral sclerosis]]
    22 KB (1,911 words) - 21:07, 21 September 2010
  • *Amyotrophic lateral sclerosis (see [[Motor Neurone Disease]]) *[[Diffuse sclerosis]]
    10 KB (889 words) - 21:07, 21 September 2010
  • * [[Tetraamelia multiple malformations]] * [[Thrombocytopenia multiple congenital anomaly]]
    9 KB (803 words) - 21:07, 21 September 2010
  • * [[Cerebellar hypoplasia endosteal sclerosis]] * [[Congenital cystic eye multiple ocular and intracranial anomalies]]
    37 KB (3,368 words) - 21:07, 21 September 2010
  • | ALS <br><small>''see'' [[amyotrophic lateral sclerosis]] </small> || || | [[amyotrophic lateral sclerosis]] || ||
    65 KB (7,342 words) - 21:07, 21 September 2010
  • ...orders that often are breed-related in dogs. Polyneuropathy indicates that multiple nerves are involved, unlike [[mononeuropathy]]. Polyneuropathy usually invo ...is]] is a consistent finding in dogs greater than seven years old. Nuclear sclerosis appears as a bilateral bluish-grey haziness at the nucleus, or center of th
    99 KB (14,444 words) - 21:22, 3 October 2011
  • ...2006 remake]], the disease has morphed into a neurological disease causing multiple [[brain tumor]]s, rapidly progressing to death within a few weeks if not tr ...ople at the beginning of the 21st century in the Repo!-verse. It creates [[Multiple organ dysfunction syndrome|massive organ failure]] and apparently has no cu
    66 KB (10,587 words) - 21:08, 21 September 2010
  • ...ynamic patterns in chronic cereblrospinal venous insufficiency in multiple sclerosis. Correlation of symptoms at onset and clinical course. |journal=Int Angiol ...found similar distribution of venous reflux in both patients with multiple sclerosis and normal controls.<ref name="Annals2">{{cite doi|10.1002/ana.22132}}</ref
    25 KB (3,509 words) - 21:29, 21 September 2010
  • ...injury. It may be effective in reducing pain and spasticity in [[multiple sclerosis]]<ref name = evid />, and has also had success in treating certain instance
    30 KB (4,025 words) - 22:06, 21 September 2010
  • ...ng accidental overdoses, most often due to confusion which arises from the multiple (and often non-acting) components of these combinations.<ref name=nps01>{{c ...viating neuropathy and pain resulting from e.g. spinal injury and multiple sclerosis.<ref>CMCR: ''CMCR Report February 17th'', California, 2010. http://www.cmcr
    14 KB (1,807 words) - 22:06, 21 September 2010
  • ...2008 |pmid=17974490|doi=10.1016/j.jpain.2007.09.002}}</ref> and [[multiple sclerosis]].<ref>{{cite journal |author= Wissel J, Haydn T, Müller J, Brenneis C, Be ...]] and [[spasticity]] neurological disorders, [[fibromyalgia]], [[multiple sclerosis]], and the nausea of [[cancer]] [[chemotherapy]].
    8 KB (1,107 words) - 22:07, 21 September 2010
  • ...rities approved the marketing of [[Sativex]], a mouth spray for [[multiple sclerosis]] to alleviate pain. Sativex contains tetrahydrocannabinol together with ca
    17 KB (2,198 words) - 22:07, 21 September 2010
  • ...the UK company [http://www.gwpharm.com/ GW Pharmaceuticals] for [[multiple sclerosis]] patients, who can use it to alleviate [[neuropathic pain]], [[spasticity] ...prescription only medicine for the treatment of spasticity due to Multiple Sclerosis. This regulatory authorization represents the world's first full regulatory
    5 KB (771 words) - 22:08, 21 September 2010
  • ...NAPE is reduced, not abolished, in low calcium concentrations, suggesting multiple, distinct pathways are involved in [[anandamide|AEA]] biosynthesis (Leung e == ECS and multiple sclerosis==
    23 KB (3,059 words) - 22:08, 21 September 2010
  • ...arijuana/index.aspx|title=Marijuana (Cannabis)|publisher=National Multiple Sclerosis Society|accessdate=2009-09-05}}</ref><br> ...rities approved the marketing of [[Sativex]], a mouth spray for [[multiple sclerosis]] patients, who can use it to alleviate [[neuropathic pain]] and [[spastici
    50 KB (6,686 words) - 22:09, 21 September 2010
  • ...asting, neuropathic pain, treatment of spasticity associated with multiple sclerosis, and chemotherapy-induced nausea," the agency has not approved "medical mar ...lingual]] spray, has been approved in Canada for the treatment of multiple sclerosis.<ref name = "SativexC">{{cite web|author = Koch, W.|date = 2005-06-23|url =
    76 KB (10,798 words) - 22:10, 21 September 2010
  • ...e there are people who have cured themselves of cancer, diabetes, multiple sclerosis, fibromyalgia, chronic pain, irritable bowel syndrome, and other diseases b ...cannabis to be beneficial to a gamut of conditions running from [[multiple sclerosis]] to [[Major depressive disorder|depression]]. Synthesized [[cannabinoids]]
    72 KB (10,341 words) - 22:11, 21 September 2010
  • ...otor neuron (MNs).''' Low Ca<sup>2+</sup> buffering in amyotrophic lateral sclerosis (ALS) vulnerable hypoglossal MNs exposes mitochondria to higher Ca<sup>2+</ ...as [[multiple sclerosis]], [[Alzheimer's disease]], [[amyotrophic lateral sclerosis]] (ALS), [[Parkinson's disease]], [[alcoholism]] or [[alcohol withdrawal]]
    11 KB (1,547 words) - 22:11, 21 September 2010
  • ...ffect]]) in patients with [[amyotrophic lateral sclerosis]] and [[multiple sclerosis]].<ref name="D+Q Trial">{{cite journal | author = Brooks B, Thisted R, Appe
    26 KB (3,444 words) - 22:15, 21 September 2010